

February 12, 2025

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers, Dalal
Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Press Release – Orchid Pharma Limited (“the Company”)

Dear Sir/Madam,

In accordance to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, kindly find enclosed the Press Release titled **“Orchid Pharma continues on a steady growth path with strengthening market position”**.

You are requested to take the above information on record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698

Encl. As above

Orchid Pharma continues on a steady growth path with strengthening market position

Q3 results show strong momentum with 26% PAT growth in YoY-9 month backed by expansion of its anti-microbial portfolio

New Delhi, 12 February 2025: Orchid Pharma Ltd., a vertically integrated pharmaceutical company spanning the entire pharmaceutical value chain from discovery to delivery has announced its **Q3 financial results for FY 2024-25**, reporting a **26% year-on-year increase in Profit After Tax (PAT)** in YoY-9 month.

This steady trajectory reflects the company's **strategic execution and ongoing expansion efforts**, particularly in the **Anti-Microbial Stewardship (AMS) division**, which is poised to drive sustained momentum.

The **Orchid AMS division is a key pillar of Orchid Pharma's long-term strategy** and has contributed significantly to the company's performance. As the division continues to gain traction, it is laying a **strong foundation for future scalability** in the critical fight against **anti-microbial resistance**.

Commenting on the results, **Manish Dhanuka, Managing Director, Orchid Pharma** said, *"We believe that our commitment to innovation and operational excellence will yield positive results. The AMS division is progressing as expected, and we are confident in its potential to drive future growth. Our focus remains on developing specialized solutions, such as our novel drug Enmetazobactam, and enhancing market reach with ORBLICEF, launched in partnership with Cipla. With a robust product pipeline and strategic R&D investments, we are well-positioned to accelerate growth in the coming quarters."*

Orchid Pharma remains dedicated to addressing global healthcare challenges through innovation, with a strong emphasis on sustainable expansion and enhanced global presence. With a pipeline of promising developments and continued operational enhancements, the company is poised for strong performance in the next phase of its growth journey.

About Orchid Pharma Limited:

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated Company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing.

Orchid, is the only Indian Pharmaceutical Company, to ever have invented a New Chemical Entity (NCE, also colloquially called New Drug). The molecule is out licensed (on Royalty model) and now approved in US and Europe.

Orchid is a pioneer in Production of Quality Cephalosporins especially the Sterile Products, for which it is the one out of the only three USFDA approved facilities in the world, and the only one from India. Besides this, the facility has other approvals like EU GMP, ANVISA and PMDA.